New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3477-3485

  Gorlia, Thierry ^a   Delattre, Jean Yves ^b   Brandes, Alba A ^c   Kros, Johan M ^d   Taphoorn, Martin J B ^e   Kouwenhoven, Mathilde C M ^d   Bernsen, H J J A ^f   Frénay, Marc ^g   Tijssen, Cees C ^h   Lacombe, Denis ^a   Van Den Bent, Martin J ^d  

^a EORTC DATA CENTER   (Belgium)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Azienda USL di Bologna   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e MEDICAL CENTER HAAGLANDEN   (Netherlands)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g PASTEUR HOSPITAL   (France)

^h CPRLab   (Netherlands)

Author keywords

Cox models; Oligoastrocytomas; Oligodendrogliomas; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CHROMOSOME 10; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CHROMOSOME LOSS; CORRELATION ANALYSIS; FACTORIAL ANALYSIS; FEMALE; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR MODEL; MUTATION; NECROSIS; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRISOMY 7;

COX MODELS; OLIGOASTROCYTOMAS; OLIGODENDROGLIOMAS; PROGNOSTIC FACTORS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOMUSTINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGODENDROGLIOMA; PATIENT SELECTION; PROCARBAZINE; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 84885188024     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.06.039     Document Type: Article

References (23)

1. M.J. van den Bent, A.A. Brandes, and M.J. Taphoorn Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951 J Clin Oncol 2012 [epub ahead of print]
2. G. Cairncross, M. Wang, and E. Shaw A phase 3 trial of chemo-radiotherapy for anaplastic oligodendroglioma: long term results of RTOG 9402 J Clin Oncol 2012 [epub ahead of print]
3. M.J. van den Bent Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective Acta Neuropathol 120 3 2010 297 304
4. J.M. Kros, T. Gorlia, and M.C. Kouwenhoven Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome J Neuropathol Exp Neurol 66 6 2007 545 551
5. M.J. van den Bent, H.J. Dubbink, and Y. Marie IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group Clin Cancer Res 16 5 2010 1597 1604
6. M.J. van den Bent, H.J. Dubbink, and M. Sanson MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951 J Clin Oncol 27 35 2009 5881 5886
7. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 10 2005 997 1003
8. M.J. van den Bent, L.A. Gravendeel, and T. Gorlia A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951 Clin Cancer Res 17 2011 7148 7155
9. S. Turcan, D. Rohle, and A. Goenka IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype Nature 483 7390 2012 479 483
10. M.J. van den Bent, A.F. Carpentier, and A.A. Brandes Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial J Clin Oncol 24 18 2006 2715 2722
11. M.J. van den Bent, A.A. Brandes, and M.J. Taphoorn Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951 J Clin Oncol 31 3 2013 344 350
12. M.C. Kouwenhoven, T. Gorlia, and J.M. Kros Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951 Neuro-oncol 11 6 2009 737 746
13. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr., and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 7 1990 1277 1280
14. D. Schoenfeld Partial residuals for the proportional hazards regression model Biometrika 69 1 1982 239 241
15. W. Sauerbrei, and M. Schumacher A bootstrap resampling procedure for model building: application to the Cox regression model Stat Med 11 16 1992 2093 2109
16. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 4 1996 361 387
17. M. Schemper, and R. Henderson Predictive accuracy and explained variation in Cox regression Biometrics 56 1 2000 249 255
18. G. Heinze, and M. Schemper Comparing the importance of prognostic factors in Cox and logistic regression using SAS Comput Methods Programs Biomed 71 2 2003 155 163
19. D. Dunkler, S. Michiels, and M. Schemper Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis? Eur J Cancer 43 4 2007 745 751
20. E.V. Slud, D.P. Byar, and S.B. Green A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data Biometrics 40 1984 587 600
21. P.D. Brown, J.C. Buckner, and J.R. O'Fallon Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma Int J Radiat Oncol Biol Phys 59 1 2004 117 125
22. P.J. French, S.M. Swagemakers, and J.H. Nagel Gene expression profiles associated with treatment response in oligodendrogliomas Cancer Res 65 24 2005 11335 11344
23. L.A. Gravendeel, M.C. Kouwenhoven, and O. Gevaert Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology Cancer Res 69 23 2009 9065 9072